Tag: MSB
What are the ASX stocks vulnerable to a ‘short squeeze’?
Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market.
It’s certainly ...
Mesoblast’s lead drug candidate achieves major regulatory milestone after US FDA vote
Shares in Australian biotech midcap Mesoblast (ASX: MSB) have hit their highest point in more than six years today, following the US Food and Drug Administration’s Oncological Drugs Advisory Committee...
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors.
Natural...
Mesoblast sees strong revenue growth as maintains busy clinical program with upcoming Ryoncil launch
In an interim performance update focusing on the past nine months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress ...
Mesoblast’s remestemcel-L drug could boost COVID-19 survival rates
Mesoblast’s (ASX: MSB) advanced remestemcel-L drug could potentially boost the survival rate of critically ill COVID-19 patients who have developed acute respiratory distress syndrome, with initial re...
Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress
Regenerative medicine company Mesoblast (ASX: MSB) has received US Food and Drug Administration Investigational New Drug (IND) clearance for its remestemcel-L treatment to be used in COVID-19 patients...
Mesoblast to trial anti-inflammatory infusions in COVID-19 patients with respiratory distress
Mesoblast (ASX: MSB) is the latest ASX company to potentially benefit commercially from the coronavirus global epidemic after revealing it would be evaluating its anti-inflammatory product in COVID-19...
Mesoblast signs manufacturing agreement with Lonza, prepares for US launch
Allogeneic cellular medicines company Mesoblast (ASX: MSB) is on track to commence manufacturing of its lead product candidate remestemcel-L courtesy of a manufacturing agreement with Swiss-listed che...
